Necrolytic migratory erythema (NME) is a rare, painful skin eruption most closely linked to glucagonoma, a tumor of the pancreas that overproduces the hormone glucagon. The rash follows a distinctive cycle of redness, blistering, crusting, and healing that shifts from one body site to another over days to weeks. In an updated review of 74 glucagonoma cases, NME appeared in roughly 93% of patients and was often the very first sign that something was wrong inside the body, showing up months or even years before the underlying tumor was found.1PubMed Central. Glucagonoma and Glucagonoma Syndrome: An Updated Review Because the rash looks so much like common skin conditions, it is routinely misdiagnosed, and the story of NME is largely a story of delayed recognition.
What the Rash Actually Looks Like
NME does not look the same from one week to the next, which is part of why it confuses clinicians. It typically starts as irregular red patches that may itch or sting. Over the following days, the patches blister, erode, and crust over. Some lesions develop a dark, necrotic center surrounded by a border of fresher redness. As one area heals, new patches appear elsewhere, giving the rash its “migratory” label. Patients often describe it as both itchy and painful, and the rash can persist for months before anyone connects it to a systemic cause.2Scientific Reports. Necrolytic migratory erythema is an important visual cutaneous clue of glucagonoma
The rash favors skin that endures friction and moisture. The groin, buttocks, perineum, and lower abdomen are classic sites. It can also appear on the extremities, face, and lower back. Individual lesions may merge into broad, map-like patches with irregular boundaries, and areas of erosion and oozing are common in the centers of older patches.3Scientific Reports. Necrolytic migratory erythema is an important visual cutaneous clue of glucagonoma This cycling pattern of spread, breakdown, crust, heal, and reappear elsewhere is the hallmark that separates NME from the more stable rashes it gets confused with.
How NME Connects to Glucagonoma Syndrome
A glucagonoma is a neuroendocrine tumor arising from the alpha cells of the pancreas, the same cells that normally produce glucagon. When a glucagonoma forms, it floods the bloodstream with glucagon far beyond normal levels. The resulting cluster of symptoms is called glucagonoma syndrome. NME is the most common feature, but it rarely travels alone. In a seven-patient series, every patient visited a dermatologist first for the rash, and more than half also had diabetes, weight loss, or anemia at the time of diagnosis.4Scientific Reports. Necrolytic migratory erythema is an important visual cutaneous clue of glucagonoma
A larger review paints a similar picture. Among 74 glucagonoma patients, about 70% had diabetes, 62% had lost significant weight, roughly 45% were anemic, and about 31% had mouth problems like glossitis, stomatitis, or cracked lips.5PubMed Central. Glucagonoma and Glucagonoma Syndrome: An Updated Review Other features reported at lower rates include diarrhea, blood clots (especially deep vein thrombosis), and neuropsychiatric disturbances.6Journal of Clinical Studies & Medical Case Reports. Necrolytic Migratory Erythema Impact on Prognosis and Diagnosis of Glucagonoma: A Case Report The combination of a bizarre, migrating rash plus new-onset diabetes in an adult who is losing weight and becoming anemic should raise a red flag for glucagonoma, yet it frequently does not.
Why the Rash Gets Misdiagnosed for Years
Glucagonoma is extremely rare. Fewer than 200 cases of NME had been reported worldwide by the mid-2000s, and while awareness has improved since then, the condition is still far off most clinicians’ radar. Because the rash cycles through different appearances, a snapshot at any single office visit can look like psoriasis, eczema, intertrigo, or contact dermatitis.7PubMed Central. Glucagonoma Syndrome With Necrolytic Migratory Erythema One published case described a woman who spent six years being treated for various common skin conditions before the true diagnosis was made.8PubMed Central. Case of delayed diagnosis of necrolytic migratory erythema Another elderly patient was managed as having eczema until additional systemic symptoms finally prompted the right workup.9PubMed Central. Necrolytic migratory erythema caused by pancreatic hyperglycemia with emphasis on therapeutic and prognosis: A case report
The problem is compounded by the fact that standard skin treatments, like topical steroids and antifungals, occasionally produce partial improvement, leading both patient and physician to believe the initial diagnosis was correct. It is usually the failure to fully clear the rash, combined with the emergence of systemic symptoms like unexplained weight loss or rising blood sugar, that eventually steers clinicians toward the right answer. By that time, the underlying tumor may have been growing for years, sometimes with metastases already present.
What Drives the Skin Damage
The exact mechanism behind NME is still debated, but the leading theory centers on nutritional depletion driven by excess glucagon. Glucagon accelerates the breakdown of proteins and fats for energy, which can drain the body’s stores of amino acids, zinc, and essential fatty acids. The skin’s outermost layers are metabolically active and depend on a steady supply of these nutrients. When levels drop, the upper epidermis essentially starves, loses structural integrity, and begins to necrose and slough off.10PubMed Central. Etiology and Pathogenesis of Necrolytic Migratory Erythema: Review of the Literature
Albumin, the most abundant protein in blood, normally carries both zinc and essential fatty acids through the circulation. When albumin drops, as it often does in glucagonoma patients, the delivery of those nutrients to the skin falters even if dietary intake is adequate. There is also a biochemical wrinkle: zinc is needed for a key step in converting dietary fats into anti-inflammatory compounds. If zinc is low, the pathway backs up and inflammatory byproducts accumulate, potentially amplifying the skin’s reaction to everyday wear and friction.11PubMed Central. Etiology and Pathogenesis of Necrolytic Migratory Erythema: Review of the Literature
This multifactorial malnutrition model is the most widely accepted explanation, but it does not tell the whole story. In one well-documented case, the rash cleared within days of surgically removing the tumor, even though the patient’s amino acid levels had not yet normalized weeks later.12The American Journal of Clinical Nutrition. Disappearance of glucagonoma rash after surgical resection, but not during dietary normalization of serum amino acids That finding suggests glucagon itself, or some other substance the tumor secretes, may play a direct role in damaging the skin beyond simply depleting nutrients. The relationship between glucagon levels, nutritional status, and NME is likely more tangled than any single-cause model can capture.
NME Without a Glucagonoma
Not every case of NME traces back to a pancreatic tumor. The same rash pattern has been reported in people with liver cirrhosis, celiac disease and other malabsorption syndromes, pancreatitis, inflammatory bowel disease, and even non-pancreatic cancers. When NME appears without a glucagonoma, the condition is sometimes called pseudoglucagonoma syndrome.13PubMed. Glucagonoma syndrome: a review and update on treatment The common thread seems to be severe nutritional depletion: anything that drastically lowers amino acids, zinc, or essential fatty acids can apparently push the skin into the same destructive cycle.
One reported case of NME without a glucagonoma responded to supplementation with essential fatty acids and zinc alone, supporting the nutritional depletion theory in a setting where glucagon levels were not elevated.14British Journal of Dermatology. Necrolytic migratory erythema without glucagonoma: the role of dietary essential fatty acids From a practical standpoint, this means finding NME on someone’s skin is not an automatic diagnosis of glucagonoma. Clinicians need to rule the tumor in or out, and if it is ruled out, investigate other causes of severe malnutrition.
Getting to a Diagnosis
When NME is suspected, two parallel tracks run at once: confirming the skin diagnosis and hunting for the underlying cause.
A skin biopsy can support the diagnosis, but the pathology findings depend heavily on which stage of the rash is sampled. Classic features include necrolysis of the upper layers of the epidermis, diffuse scaling changes in the surface layer, and sometimes separation of cells in the middle epidermis. In a study of 13 cases, only about two-thirds of the biopsies showed features considered characteristic; the rest were ambiguous or nonspecific.15PubMed. Necrolytic migratory erythema: clinicopathologic study of 13 cases Occasionally, the biopsy mimics other conditions entirely. One case initially showed a pattern of cell separation that pointed toward a blistering autoimmune disease; only a second biopsy from a different lesion revealed the upper-layer necrolysis typical of NME.16PubMed. Suprabasal acantholysis–an unusual feature of necrolytic migratory erythema Biopsying a fresh, actively expanding lesion rather than an older crusted one increases the chances of catching the diagnostic features.
When biopsy results are suggestive, the next step is a blood test for glucagon. In glucagonoma, levels are markedly elevated. In the seven-patient series mentioned earlier, plasma glucagon ranged from about 217 to over 3,100 pg/mL, far above the normal range.17Scientific Reports. Necrolytic migratory erythema is an important visual cutaneous clue of glucagonoma If glucagon is elevated, imaging follows to locate the tumor. Standard cross-sectional imaging like CT or MRI can find larger tumors, but specialized nuclear medicine scans using a radiotracer called 68Ga-DOTATATE are considered particularly useful for well-differentiated glucagonomas because these tumors typically carry receptors that the tracer binds to with high accuracy.18PubMed Central. Molecular imaging of a glucagonoma with 18F-FDG PET/CT and 68Ga-DOTATATE PET/CT imaging: A case report and review of the literature This type of scan also helps determine whether the patient might benefit from a targeted radiation treatment that uses the same receptor pathway.19PubMed. A Case Series of Molecular Imaging of Glucagonoma After Initial Therapy-68Ga-DOTATATE PET/CT Reveals Similar Results as in Neuroendocrine Tumors of Other Origin in Follow-up and Re-evaluation
Surgical Removal and How Quickly the Skin Responds
When the glucagonoma can be completely removed, the results for the skin are often dramatic. In one series of six patients who underwent surgery, all saw their rash begin to clear within a day to a week, and postoperative glucagon levels dropped sharply, sometimes returning to normal.20Scientific Reports. Necrolytic migratory erythema is an important visual cutaneous clue of glucagonoma Another case report described rapid symptom relief after the pancreatic tumor was removed.21PubMed Central. Glucagonoma syndrome: A case report Surgery is the only treatment that addresses the root cause, and when the tumor is localized without distant spread, it can be curative. Identifying NME early enough to catch the tumor before metastasis is exactly why dermatologists and internists need to know about this rash.22PubMed Central. Necrolytic Migratory Erythema as the First Manifestation of Functional Conversion in a Glucagonoma: A Case Report
The speed of skin clearance after surgery is itself a clue about pathophysiology. If nutritional depletion alone explained NME, you would expect the rash to linger until amino acid and zinc stores were rebuilt, which takes weeks. The fact that the skin starts healing within a day or two of tumor removal suggests that the high glucagon levels, or something else the tumor secretes, are actively driving the rash in real time.
Managing NME When Surgery Is Not Possible
Many glucagonomas are diagnosed after the tumor has already spread, most often to the liver. In those cases, complete surgical removal is not feasible, and symptom control becomes the priority. The two main medical strategies are somatostatin analogs and nutritional support, sometimes used together.
Somatostatin analogs like octreotide suppress glucagon secretion and have become a mainstay. In a scoping review of 25 patients treated with these drugs, about 80% showed improvement in their skin lesions, with an average time to visible improvement of roughly six weeks, though some patients responded within 24 hours.23Case Reports in Dermatology. Exceptional Response of Necrolytic Migratory Erythema to Octreotide in a Patient with Glucagonoma: A Case Report and Scoping Review About one in six patients did not respond to somatostatin analogs at all. For advanced disease, combining octreotide with chemotherapy agents has shown promise in individual cases.24PubMed Central. Application of Somatostatin, Chemotherapy Combined with TAE in Heterogeneous Glucagonoma Presented with Necrolytic Migratory Erythema
Nutritional supplementation takes a different angle. Since the rash appears linked to depletion of amino acids, zinc, and essential fatty acids, intravenous infusions of these nutrients can produce significant improvement even when the tumor remains in place. One patient was managed for two full years with intermittent intravenous amino acid infusions, and adding lipid infusions extended the intervals between treatments.25PubMed Central. A case of necrolytic migratory erythema managed for 24 months with intravenous amino acid and lipid infusions In another case, the NME cleared with amino acid and fatty acid infusions administered through a regular peripheral IV line for over a year, even though blood levels of these nutrients did not measurably change, which is itself a puzzle.26PubMed. Peripheral amino acid and fatty acid infusion for the treatment of necrolytic migratory erythema in the glucagonoma syndrome
In some patients, intravenous amino acids succeed even after other treatments have failed. One case report described a woman whose NME recurred after somatostatin therapy, surgical debulking, and chemotherapy all proved inadequate, but who achieved control of her skin disease with amino acid infusions.27PubMed. Treatment of necrolytic migratory erythema in glucagonoma syndrome This makes nutritional support an important fallback and sometimes a first-line add-on, particularly for patients who are visibly malnourished or have very low albumin.
What a Skin Biopsy Can and Cannot Tell You
Clinicians sometimes expect a biopsy to clinch the NME diagnosis the way it might for psoriasis or a blistering disease, but the histopathology of NME is notoriously fickle. The textbook finding is a band of dead and dying cells in the upper epidermis with a relatively preserved lower layer, plus scaling changes at the surface. In practice, the picture depends on where in the rash cycle the biopsy lands. An early lesion may show only mild inflammation that looks like garden-variety dermatitis. A late, crusted lesion may show so much damage that the architecture is unreadable.
The study of 13 cases mentioned earlier found that diffuse surface scaling was the most consistent finding, present in 12 of 13 biopsies, but the full pattern considered characteristic appeared in only about eight.28PubMed. Necrolytic migratory erythema: clinicopathologic study of 13 cases The practical lesson is that a negative or inconclusive biopsy does not rule out NME. If the clinical picture is suspicious, particularly a migratory erosive rash in someone with new diabetes and weight loss, the right move is to check glucagon levels regardless of what the biopsy shows.
Conditions That Mimic NME and Vice Versa
The list of look-alikes is long enough to explain why misdiagnosis is common. Psoriasis, seborrheic dermatitis, pemphigus, zinc-deficiency dermatitis (acrodermatitis enteropathica), and even drug reactions can produce overlapping features. In settings where NME occurs without a glucagonoma, the associations expand further. A review of nonglucagonoma-associated NME found that the most commonly linked conditions were celiac disease or other malabsorption syndromes, cirrhosis, non-pancreatic malignancies, and pancreatitis, with less common associations including hepatitis, inflammatory bowel disease, and heroin use.
Distinguishing NME from these mimics usually relies on the migratory pattern, the specific body sites involved, the systemic symptoms (diabetes, weight loss, anemia), and ultimately the glucagon level. No single feature is pathognomonic on its own, which is why experienced clinicians emphasize pattern recognition over any one test. A rash that cycles through erythema, erosion, crusting, and healing while drifting across the groin and buttocks in a patient whose blood sugar is climbing and whose weight is falling should trigger a glucagon measurement even if the biopsy is equivocal and even if the rash initially responded to a short course of steroids.
Why Earlier Recognition Changes Outcomes
Glucagonomas are slow-growing tumors, and many patients live for years even with metastatic disease. But outcomes are far better when the tumor is caught while still localized. The rash is often the earliest and most visible sign, appearing well before the tumor has had time to spread. The updated review noted that more recent case series show earlier ages of diagnosis and higher rates of NME recognition, consistent with improved diagnostic awareness among dermatologists and endocrinologists.29PubMed Central. Glucagonoma and Glucagonoma Syndrome: An Updated Review Still, delays of several years remain common. The six-year diagnostic delay in one published case is not an outlier; it reflects how easily NME blends into the landscape of chronic, irritating skin problems that patients and physicians manage with topical treatments without ever questioning the underlying cause.30PubMed Central. Case of delayed diagnosis of necrolytic migratory erythema
For patients, the practical implication is straightforward: a rash that migrates, erodes, and keeps coming back despite treatment, especially alongside new blood sugar problems or unexplained weight loss, is worth pushing your doctor to investigate beyond the usual dermatitis workup. For clinicians, NME is one of those rare diagnoses where recognizing a skin pattern can lead directly to finding a curable tumor before it metastasizes. The skin, in this case, is genuinely trying to tell you something about the pancreas.